SKY-LABS
22.2.2021 15:02:11 CET | Business Wire | Press release
Sky Labs , a healthcare start-up, announced that CART-I, its ring-type heart-monitoring device, had been provided for Timothy Betts, professor of medicine at Oxford University, for his clinical research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005010/en/
Professor Timothy Betts is a cardiologist and arrhythmia specialist. He is a key figure for clinical research in cardiac rhythm management and associate professor of cardiovascular medicine at Oxford University. He is also a member of the Oxford Biomedical Research Center and the UK representative on the EHRA National Cardiac Societies Committee.
Atrial fibrillation patients are advised to take anticoagulants to prevent the risk of stroke. However, it is not easy to identify the symptoms. Professor Betts plans to conduct a clinical study with Sky Labs CART-I, Medtronic Reveal LINQ II and Apple Watch to detect atrial fibrillation symptoms and alert the patients to take anticoagulants when needed.
Fifty patients recruited for the study will be inserted with a Reveal LINQ II implantable cardiac monitor (ICM). Then they will receive a Sky Labs CART-I ring or an Apple Watch. The ability of the ring and the watch to monitor heart rhythm and alert atrial fibrillation episodes will be analyzed in comparison with the ICM.
CART-I is the world’s first ring-type heart-monitoring device. The photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger and continuously measures the irregular pulse waves of atrial fibrillation. Electrocardiogram (ECG) can be also measured by simply placing the fingers on the metal part of the ring.
Professor Timothy Betts said, “I’m pleased to conduct a study to monitor the atrial fibrillation of patients by using CART-I and utilize the data to guide atrial fibrillation treatment. CART-I featuring innovative design and multiple functions will be of great help to patients and medical staffs.”
Jack Lee, CEO of Sky Labs, said, “The study will be an opportunity for us to enter the global healthcare market. CART-I will make a good combination with the ICM in monitoring heart rhythm and providing meaningful data for patients and doctors.”
Sky Labs’ CART-I won the Digital Health & Technology Competition of the European Society of Cardiology for 2 consecutive years from 2018. The company was selected as the ‘technology pioneer’ of the World Economic Forum 2019 and invited to the annual forum.
About Sky Labs
Sky Labs developed CART (Cardio Tracker) – I, a ring-type medical device to monitor heart signals and detect diseases by using optical sensors. It monitors atrial fibrillation, which cannot be detected in advance, 24/7. The results can be checked in real time on the CART-app of your smartphone. Very light and water-resistant, the CART ring is easy to use and causes no inconvenience to your daily life. Winning the final of the Grants4Apps held by Bayer, a German multinational pharmaceutical company, in 2017, Sky Labs attracted investment from Bayer Headquarters. Sky Labs and the Charité in Germany, one of Europe’s largest hospitals, have been considering collaborative clinical research in heart-related diseases since May 2018. It is the only Korean company which won the Digital Health and Technology Competition of the European Society of Cardiology for 2 consecutive years. In addition, the company was invited as a technology pioneer to the World Economic Forum 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 1018.8.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818490253/en/
Lehman Brothers Treasury Announces the Successful Sale of its Remaining Intercompany Claim against Lehman Brothers Holdings Inc.18.8.2026 21:15:00 CEST | Press release
In connection with its previously announced final wind-down, Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”), through its U.S. counsel Herbert Smith Freehills Kramer (US) LLP, announced that its placement agent, Seaport Loan Products LLC, successfully closed the sale of LBT’s remaining $19.6 billion Class 4A intercompany claim against Lehman Brothers Holdings Inc. The net proceeds of the sale, together with certain available cash (but after deducting various sale-related and other administrative costs and expenses), will be used to fund a final distribution to the holders of LBT’s existing notes, after which such existing notes will be canceled and LBT shall be fully wound down. As a result, LBT will cease to exist. LBT expects the final distribution to occur in the course of October 2026 and the wind down to have been completed before the end of 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818004215/en/
GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release
Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release
- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
